Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Eikon Therapeutics IPO $381.2M January 2026 Eikon Therapeutics priced an upsized IPO of 21,177,600 shares at $18.00 per share, generating expected gross proceeds of approximately $381 million before underwriting discounts, commissions, and expenses
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest
Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course: post hoc analysis of a prospectively collected international registry
Yang, M., So, K., Lam, W.C., and Lo, A.C.Y., Novel Programmed Cell Death as Therapeutic Targetsin Age-Related Macular Degeneration
.png)
That did not work for me
US$ 24.33
US$ 27.41
US$ 29.72
US$ 25.13
US$ 22.88
